267 related articles for article (PubMed ID: 29496465)
1. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab.
Kuruvilla M
Ann Allergy Asthma Immunol; 2018 Jun; 120(6):670-671. PubMed ID: 29496465
[No Abstract] [Full Text] [Related]
2. [Anti-interleukin-5 therapy for eosinophilic diseases].
Simon D; Braathen LR; Simon HU
Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment with mepolizumab in a patient with refractory Wells syndrome.
Terhorst-Molawi D; Altrichter S; Röwert J; Magerl M; Zuberbier T; Maurer M; Bergmann KC; Metz M
J Dtsch Dermatol Ges; 2020 Jul; 18(7):737-739. PubMed ID: 32713149
[No Abstract] [Full Text] [Related]
4. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
Plötz SG; Simon HU; Darsow U; Simon D; Vassina E; Yousefi S; Hein R; Smith T; Behrendt H; Ring J
N Engl J Med; 2003 Dec; 349(24):2334-9. PubMed ID: 14668459
[No Abstract] [Full Text] [Related]
5. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
6. L6. Eosinophilic granulomatosis with polyangiitis: future therapies.
Moosig F
Presse Med; 2013 Apr; 42(4 Pt 2):510-2. PubMed ID: 23453508
[No Abstract] [Full Text] [Related]
7. Mepolizumab use: Post-approval academic practice experience.
Benjamin MR; Bochner BS; Peters AT
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):126-128. PubMed ID: 29653234
[No Abstract] [Full Text] [Related]
8. Tolerance and Efficacy with Simultaneous Use of Two Monoclonal Antibodies for a Patient with Hypereosinophilic Syndrome and Ulcerative Colitis.
Patel B; Butterfield JH; Weiler CR; Kane SV
Monoclon Antib Immunodiagn Immunother; 2016 Dec; 35(6):300-303. PubMed ID: 27911676
[TBL] [Abstract][Full Text] [Related]
9. Changing roles of eosinophils in health and disease.
Furuta GT; Atkins FD; Lee NA; Lee JJ
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):3-8. PubMed ID: 24795292
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
11. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases.
Schmid-Grendelmeier P; Altznauer F; Fischer B; Bizer C; Straumann A; Menz G; Blaser K; Wüthrich B; Simon HU
J Immunol; 2002 Jul; 169(2):1021-7. PubMed ID: 12097410
[TBL] [Abstract][Full Text] [Related]
12. Diagnoses associated with peripheral blood eosinophilia: A 5-year review.
Leverone N; Tran S; Barry J; Akuthota P
Ann Allergy Asthma Immunol; 2021 Nov; 127(5):597-598. PubMed ID: 34391899
[No Abstract] [Full Text] [Related]
13. Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME; Klion AD; Roufosse FE; Kahn JE; Weller PF; Simon HU; Schwartz LB; Rosenwasser LJ; Ring J; Griffin EF; Haig AE; Frewer PI; Parkin JM; Gleich GJ;
N Engl J Med; 2008 Mar; 358(12):1215-28. PubMed ID: 18344568
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab in the treatment of severe eosinophilic asthma: Results from a physician in the field.
Strauss RA; Jawhari N
Ann Allergy Asthma Immunol; 2018 Jul; 121(1):121-123. PubMed ID: 29684570
[No Abstract] [Full Text] [Related]
15. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
16. Eosinophils in mucosal immune responses.
Travers J; Rothenberg ME
Mucosal Immunol; 2015 May; 8(3):464-75. PubMed ID: 25807184
[TBL] [Abstract][Full Text] [Related]
17. Clinical Course of Eosinophilic Cellulitis.
Ozawa H; Kuwano K; Manabe S; Ishihara T; Komatsu M; Kobayashi T; Yanagi H; Oki M; Takagi A
Tokai J Exp Clin Med; 2017 Dec; 42(4):143-146. PubMed ID: 29228410
[TBL] [Abstract][Full Text] [Related]
18. Current update on eosinophilic lung diseases and anti-IL-5 treatment.
Samitas K; Rådinger M; Bossios A
Recent Pat Antiinfect Drug Discov; 2011 Sep; 6(3):189-205. PubMed ID: 21824072
[TBL] [Abstract][Full Text] [Related]
19. Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions.
Harish A; Schwartz SA
Clin Rev Allergy Immunol; 2020 Oct; 59(2):231-247. PubMed ID: 31919743
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recalcitrant eosinophilic cellulitis with adalimumab.
Sarin KY; Fiorentino D
Arch Dermatol; 2012 Sep; 148(9):990-2. PubMed ID: 22986848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
